Introduction
Staphylococcus aureus bacteraemia (SAB) is common and serious, with an estimated 6900 cases occurring in Australia annually 1 and a contemporary 30-day mortality of 16.1%. 2 Management of SAB is a core service responsibility of infectious disease services. management of SAB is also of interest to the broader clinical community, with 87% of SAB cases being admitted under non-infectious disease home teams. 4 There remain important questions regarding the optimal investigations and treatment of SAB. Management of SAB has been identified as one of the key areas for ongoing clinical research by the Australasian Society for Infectious Diseases Clinical Research Network. 5 Bacteraemia can occur secondary to a wide range of sources, with skin and soft tissue sources predominating in community-onset SAB, while infected vascular access devices, surgical site infections and infected prosthesis are more common in healthcare-associated SAB. 6 S. aureus is highly virulent and is associated with haematogenous seeding of infection in up to 34% of cases. 7 These features of SAB mandate repeat blood cultures until clearance of bacteraemia is confirmed, a careful assessment for primary and secondary sites of infection and a minimum 14-day course of intravenous (IV) antibiotics. 8, 9 Administration of these prolonged courses of IV antibiotics is increasingly occurring through peripherally inserted central catheter (PICC); these allow safe and reliable IV access for inpatients and, when appropriate, allow for treatment to be completed through outpatient IV antibiotic programmes.
However, there is a concern that early PICC insertion, particularly within the period of bacteraemia, may predispose to S. aureus infection of the new line. Consequently, the practice at some centres is to delay PICC insertion until clearance of bacteraemia can be demonstrated by negative blood cultures. Reflecting these clinical concerns, the guidelines around PICC use remain cautious regarding insertion during periods of bacteraemia, with recommendations for delayed insertion; notably, these recommendations are based on expert consensus only. 10 There is currently no published evidence to support or refute this practice. Delays in PICC insertion can delay establishment of safe reliable IV access for antibiotic administration. These delays can also prolong the length of inpatient stay by impeding transfer to outpatient IV antibiotic programmes.
This single-centre, retrospective audit compared the outcomes for patients with SAB and early PICC insertion with outcomes of patients with SAB and late PICC insertion. We considered the primary outcomes measures of duration of bacteraemia, confirmed PICC infection, SAB relapse and attributable mortality.
Methods
Patients were eligible for inclusion in this study if they had a positive blood culture for S. aureus from samples collected at Princess Alexandra Hospital between March 2013 and September 2016 and had a PICC inserted during their subsequent treatment. Early PICC insertion was defined as occurring within 48 h of the first positive blood culture; late PICC insertion was defined as occurring later than this but prior to completion of IV antibiotic therapy. The duration of bacteraemia was determined from the number of days, inclusive, between the first and last positive blood cultures time periods were measured in 24-h increments based on the date of the event being recorded, and patients with a single positive blood culture were assumed to have a 1-day duration of bacteraemia. We assessed for the outcomes of crude mortality, attributable mortality at 30 days, Catheter-Related Blood Stream Infection (CRBSI) from the PICC, duration of bacteraemia and relapsed SAB.
Presence and duration of SAB, timing of clearance cultures and culture-positive PICC tips were identified from the state-wide laboratory information service (Auslab). The medical record of each case was reviewed to collect demographic data and timing of PICC insertion. We defined a PICC CRBSI as per the Infectious Diseases Society of America, with continuing or recrudescent positive blood cultures with S. aureus in association with a positive culture of the PICC tip after removal. 11 The Australian Commission on Safety and Quality in Health Care catheter-associated BSI guidelines, defined as new positive blood cultures, in association with a central line in situ for >2 calendar days 12 were inappropriate for this study as they are a surveillance tool intended to identify catheter-associated BSI rather than demonstrate a causative role and could have classified ongoing bacteraemia after insertion of a PICC line as a CRBSI. Relapse was defined as microbiologically confirmed SAB occurring greater than 2 days and less than 365 days after the first negative blood culture. We performed sub-analyses of patients with methicillin-resistant S. aureus (MRSA) and of those who received a PICC within the period of confirmed bacteraemia, as defined by positive blood cultures on the day of, or subsequent to, PICC insertion. Information regarding source of infection and treatment was obtained by cross-referencing cases with the local Australian Group on Antimicrobial Resistance prospective dataset. The medical records of patients who died were reviewed independently by both authors to determine if these deaths were attributable to the SAB; factors considered included ongoing bacteraemia, uncontrolled signs and symptoms of infection or otherwise unexplained death. 13 Data were de-identified and recorded in a secure electronic database (excel). Statistical analysis was performed using statistical software (Stata 13, Stata Statistical Software: Release 13, 2013; StataCorp., College Station, TX, USA). Categorical values were analysed by Fisher's exact test and continuous values analysed using Student's t-test. Given the right skewed distribution in duration of bacteraemia, these differences were analysed using the Mann-Whitney U-test.
This retrospective quality assurance study was submitted to the Metro South Human Research Ethics Committee and received an exemption from ethical review (HREC/16/QPAH/756).
Results
Our study identified 433 patients with SAB, of whom 357 subsequently received a PICC. The median duration to PICC insertion was 5 days (Fig. 1) . The overall 30-day mortality in the total population was 15% (65/433), with a mortality of 53% (40/76) in the subset not receiving a PICC as compared to 7% (25/357) in the population receiving a PICC.
No significant differences in the populations who received an early or late PICC were identified (Table 1) . There was a trend towards increased intensive care unit (ICU) admissions among the group with late PICC insertion; this reflects the alternative lines used for central venous access in the ICU.
The focus of the SAB was similar among the early and late PICC insertion groups (Table 2 ). There was a trend towards increased device-associated infection as the initial focus of SAB among the early PICC insertion group. This, in part, indicates the subset of patients with ongoing requirements for central or reliable IV access, which prompted early PICC insertion.
Attributable outcomes were similar for both early and late PICC insertion. Our population had a mean duration of bacteraemia of 3.7 and 3.3 days in the early and late PICC insertion groups, respectively, with a median bacteraemia duration of 2 days in both groups (Table 3) . Among all patients receiving a PICC, 48.5% (173/357) had a duration of bacteraemia of 1 day. Eleven patients did not have clearance blood cultures performed, and this may underestimate the duration of bacteraemia for this subset. Attributable mortality was similar in the early and late PICC insertion groups (Table 3 ). However, there was an increased crude 30-day mortality rate in the early PICC insertion group as compared to late PICC insertion ( Table 3 ). The increased crude 30-day mortality rate in the population not receiving any PICC (53%, 40/76) as compared to the population receiving a PICC No confirmed PICC CRBSI were identified in this study. However, there was a single S. aureus culturepositive catheter tip identified. This case was a culturepositive PICC tip in a patient with a late PICC insertion and negative blood cultures 5 days prior to line removal, with no subsequent relapse of bacteraemia. In the absence of bacteraemia, this result does not meet criteria for CRBSI as per the Infectious Diseases Society of America or The Australian Commission on Safety and Quality in Health Care Catheter-associated BSI criteria; 11, 12 instead, this may represent contamination of the PICC tip at the time of removal. Line tips are not routinely cultured in the absence of confirmed bacteraemia due to this risk of contamination.
14 There were 15 cases of SAB relapse identified in the cohort with PICC. The rate was no different in the early PICC group (3/64, 4.7%) as compared to the late PICC group (12/293, 4.1%) (P = 0.83).
There is typically a longer duration of bacteraemia in SAB secondary to MRSA, 7 and this could increase the risk of subsequent infection of the PICC line. As such, we performed a sub-analysis of patients with SAB secondary to MRSA. There were no significant differences in duration of bacteraemia, relapse, attributable mortality or CRBSI in the subset of patients with MRSA SAB, although there was a difference in crude mortality (Table 4) .
We also performed a sub-analysis of patients who received a PICC within the period of confirmed bacteraemia. This group included 67 patients, of which 27 had early PICC insertion and 40 had late PICC insertion. There were no PICC CRBSI among the group receiving a PICC line while still bacteraemic.
Discussion
This study suggests that early PICC insertion in SAB is safe, with no differences between the early and late PICC insertion groups in attributable mortality, duration of bacteraemia and relapsed SAB. Importantly, there were no PICC CRBSI in either group.
The difference in crude mortality is notable. However, we believe this result to be confounded by several factors. We acknowledge that the determination of deaths as being attributable to SAB is made difficult by the multiple factors that contribute to outcomes and is vulnerable to interpretive bias. 15 Patients in the early PICC insertion group were more likely to have preexisting medical conditions that mandated prolonged IV access and PICC insertion, often prior to the recognition of SAB, although this dataset does not include formal comorbidity scores. The timings of the nonattributable deaths were also relatively distant from onset of bacteraemia, occurring a median 26 days postbacteraemia as compared to 16 days for the attributable deaths, which also suggests a greater role for non-sepsis mechanisms. Additionally, the lack of difference in other outcome measures argues against any mechanistic role that early PICC insertion could have had in increasing mortality.
PICC infections occur at a rate of approximately 2 per 1000 patient days. 16 The risk of line infection is increased by the formation of a non-infective biofilm on the external surface of the catheter within 3 days of insertion as well as subsequent intra-luminal biofilm formation. 17 The concerns around secondary infection of the PICC have biological plausibility. Antibiotic therapy does not lead to immediate sterilisation of the blood stream, with a typical mean duration of bacteraemia of 3 days for MSSA and 9 days for MRSA bacteraemia. 7 Haematogenous infections of lines are well described. 18, 19 However, the risk of this complication developing is not understood in the presence of effective antimicrobial therapy at the time of line insertion, as is the case in this study population. The presence of appropriate antibiotics may be adequate to prevent the establishment of a microbial biofilm on the PICC even in the presence of persistent bacteraemia. This may be analogous to the situation in prosthetic joint infection revision surgery where singlestage revisions, with a new prosthesis being implanted into a potentially non-sterile site, still lead to the cure of infection in 90-95% of cases at 5 years. 20, 21 Similarly, central venous access is often required for communityonset septic shock requiring ICU admission; when blood cultures taken at admission subsequently become positive, it does not routinely indicate a line change. There remains the possibility that microbial seeding of the PICC occurs at the time of insertion and that this infectious inoculum remains suppressed while there is ongoing administration of antibiotics. Most patients with a SAB and subsequent PICC have the line removed at the completion of antibiotic therapy. There is a potential risk for shearing of infected biofilm at the time of removal, with subsequent haematogenous seeding of infection. 17 Our study did not demonstrate any increased relapse rates in the cohort receiving early PICC insertion, indicating that this process, if occurring, was unlikely to be clinically significant.
There was a reduced proportion of patients with ICU admission in the early PICC insertion group, which was due to the alternative lines used for establishing IV access in the critical care setting. We do not consider this a weakness of the study. The rationale for early PICC access is the establishment of reliable IV access and potentially to expedite discharge in patients with early clinical improvement and no metastatic source of infection identified, which requires further intervention. Neither of these criteria is relevant to the shocked patient with SAB requiring ICU admission.
Our institution contributes to the Australian Group on Antimicrobial Resistance data, which include ongoing surveillance of SAB. No significant differences have been noted in our population with SAB, compared with aggregated Australian data, other than a slightly lower MRSA rate, for which there is significant state-to-state variation within Australia. 6 This indicates that our population is representative of the broader Australian population with SAB and that our results are externally applicable.
This study has some shortcomings. The absence of any confirmed PICC CRBSI in this study raises the possibility of this study being underpowered for this outcome measure. There are no published data on the rates of PICC CRBSI occurring during a SAB while receiving appropriate antimicrobial therapy. As such, we were unable to perform a power calculation prior to data collection. The absence of any PICC CRBSI in the 357 patients suggests that this is a rare event. It is possible that infected PICC tips were not sent for culture; however, this is unlikely given that the infectious diseases unit consults closely on all cases of SAB and would recommend tip culture in cases of suspected PICC infection. Our relapse data are limited by the absence of strain typing to distinguish SAB relapse from recurrence. Finally, the retrospective nature of this study, and lack of comorbidity assessment, cannot exclude the impact of unappreciated confounders, a factor discussed above with respect to the different crude mortality rates.
Conclusion
In summary, our data suggest that the risk of PICC infection secondary to SAB in the presence of effective antimicrobial therapy is low, and there was no apparent increased risk with early PICC insertion or insertion during bacteraemia. Given the limitations inherent in a retrospective audit, these results require validation in a prospective study with formal comorbidity assessment. If validated, these findings should impact routine management of SAB and increase the safety and reliability of IV access and delivery of IV antibiotics, as well as facilitate early discharge to outpatient antibiotic programmes for patients with uncomplicated SAB.
